Arkolith/Insider Trading/ZNTL/Form 4

Skvarka Jan

DirectorZentalis Pharmaceuticals, Inc. (ZNTL) · full profile →Form 4 · filed Sep 13, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$125K
Net Open-Market Flow
-$125K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 11, 2023Sell(S)5K$25.05$125K48K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001725160-23-000162) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML